PATENT CLAIM ANALYSIS

Application Number: 15918868
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["544", "359000"]

Abstract:
The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.

Claim (Index 7):
A pharmaceutical composition comprising a non-solvated crystalline micronized free-base form of the compound 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is Form I, having an X-ray powder diffraction pattern comprising at least one peak, in terms of 2\u03b8 at 4.50\u00b10.2\u00b0, and one or more pharmaceutically acceptable excipients.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 90.0
- Lexical Diversity: 1.27778
- Patent Class: 544.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14865370', '12970785', '15150999', '13457867', '14381289']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6987162100156438
- 35 USC 102 Novelty (BERT): 0.4945982739358853
- Combined Prediction Score: 0.6783044164076679
- Mean Citation Score: 241.730324
- Max Citation Score: 251.20502
- Similarity Product: 204.6051646989036

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test